Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multiple-Center, Open-Label, Study of the Safety and Efficacy of Oral NRX 194204 Capsule Administered Daily for a Minimum of 4 Weeks in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT00964132 is registered in ClinicalTrials.gov with NuRx Pharmaceuticals, Inc. as lead sponsor.

NCT NCT00964132
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00964132 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multiple-Center, Open-Label, Study of the Safety and Efficacy of Oral NRX 194204 Capsule Administered Daily for a Minimum of 4 Weeks in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Lead sponsor
NuRx Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Unknown status
Start date
March 31, 2009
Completion date
June 30, 2010
Enrollment
48 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer